Prognosis and Survival in Idiopathic Pulmonary Fibrosis in the Era of Antifibrotic Therapy in Italy: Evidence from a Longitudinal Population Study Based on Healthcare Utilization Databases

Int J Environ Res Public Health. 2022 Dec 12;19(24):16689. doi: 10.3390/ijerph192416689.

Abstract

The aim was to evaluate the determinants of acute exacerbation (AE) and death in new cases of idiopathic pulmonary fibrosis (IPF) using administrative databases in the Marche Region. Adults at their first prescription of antifibrotics or hospitalization with a diagnosis of IPF occurring in 2014-2019 were considered as new cases. Multiple Cox regression was used to estimate the risk of AE and of all-cause mortality adjusted by demographic and clinical characteristics, stratifying patients according to antifibrotic treatment. Overall, 676 new cases of IPF were identified and 276 deaths and 248 AE events occurred. In never-treated patients, the risk of AE was higher in patients with poor health conditions at diagnosis; the risk of death was higher in males, in patients aged ≥75 and in those with poor health conditions at baseline. The increasing number of AEs increased the risk of death in treated and never-treated patients. Within the limits of an observational study based on secondary data, the combined use of healthcare administrative databases allows the accurate analysis of progression and survival of IPF from the beginning of the antifibrotic therapy era, suggesting that timely and early diagnosis is critical to prescribing the most suitable treatment to increase survival and maintain a healthy life expectancy.

Keywords: acute exacerbation; idiopathic pulmonary fibrosis; real-world evidence; secondary health databases; survival analysis.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Delivery of Health Care
  • Disease Progression
  • Humans
  • Idiopathic Pulmonary Fibrosis* / drug therapy
  • Italy / epidemiology
  • Male
  • Patient Acceptance of Health Care
  • Retrospective Studies

Grants and funding

This study was funded by a grant from the Italian Ministry of Education, University and Research (Progetti di Ricerca di Rilevante Interesse Nazionale, PRIN 2019–2021, “Modelling effectiveness, cost-effectiveness and promoting health care value in the real world” project, project number 2017728JPK).